Synopsis
Assess suspected and incidental meningioma, relate symptoms to location and mass effect, and explain how tumour growth, grade, resection extent, procedural risk and patient priorities shape observation, surgery or radiotherapy.
- Meningiomas arise from meningothelial cells and are usually extra-axial; many are incidental, but symptoms depend on location, size, oedema, venous involvement and pressure effects.
- Standard contrast-enhanced structural MRI is the initial diagnostic test under NICE NG99; add CT when bone involvement or hyperostosis needs assessment.
- Observation is appropriate for many incidental asymptomatic suspected meningiomas, while growing or symptomatic lesions prompt specialist discussion of surgery or radiotherapy.
Key red flags
New seizure, persistent postictal deficit or failure to recover usual consciousness.
Rapidly worsening focal weakness, speech or visual change, gait impairment, pupil abnormality or declining alertness.
Papilloedema, repeated vomiting or progressive headache with drowsiness suggesting significant oedema, hydrocephalus or mass effect.
Progressive visual loss, optic atrophy or field defect with a skull-base, planum, sphenoid-wing or parasellar lesion.
Documented growth, new neurological symptoms or radiological features atypical for a routine grade 1 tumour.
Headache, vomiting, papilloedema and drowsiness can occur with large tumours, extensive oedema or obstruction of CSF pathways. Acute change requires emergency imaging despite an earlier slow-growth pattern.
Investigation priorities
Define the suspected extra-axial lesion, enhancement, dural attachment, oedema, venous-sinus relationship and proximity to eloquent structures.
Management branches
Imaging for another reason shows a small typical meningioma without neurological deficit or threatened function.
- Confirm that symptoms do not localise to the lesion, review prior imaging and assess age, comorbidity, tumour site, oedema and intervention risk.
- Discuss at the appropriate specialist service and agree active monitoring when expected benefit of immediate treatment is low.